SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

    C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

  • We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 MUfGeY5kfGmxbjDBd5NigQ>? NFTFPXczPSEQvF2= MVuzNEBucW5? NEO4PZpFVVORwrC= MUHheJRmdnWjdHXzJJRp\SCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25ib3[gbGJFNTJiaX6gdoV{eG:wc3n2[UB1dyCGQR?= NYHlU2JUOjZ{MkOyOVE>
MDA-MB-231 NITiOY9HfW6ldHnvckBCe3OjeR?= M1z2fVIh|ryP MWmyOEBp NXLVXHB6dGW|c3Xu[ZMhS0OOMjDpcoR2[3Srb36gZpkhXE6IzsG= M37OWlI3OTByOES4
rBMSCs MkHlSpVv[3Srb36gRZN{[Xl? NFjufHgyOCEQvF2= NEP3VJEzNjViaB?= MXjk[ZBz\XO|ZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCHUlugZY5lKHB|OB?= NYXRe49kOjZyNUOyOlY>
MG63 NXL0eHQzTnWwY4Tpc44hSXO|YYm= MmK3NVAwOjBxM{Cg{txO NUDKTZlHOjRiaB?= NVGwO4gze2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>? NVi2VpZbOjV7OUizNVI>
MG63 M3rlUGFxd3C2b4Ppd{BCe3OjeR?= NULIOphYOTBxMkCvN|Ah|ryP MUGyOEBp NIHIT21{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{ MYWyOVk6QDNzMh?=
HTSMCs NGHrXnFHfW6ldHnvckBCe3OjeR?= M2Xj[|AvOS9zL{GwJO69VQ>? NFHmOXAyKGh? MWfpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO|aX;u M{\UdVI2QTJzNE[0
MIA PaCa-2 MoPFSpVv[3Srb36gRZN{[Xl? MVeyNOKh|ryP Mn7lNlQhcA>? NGrPRolz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh MnnONlU5QDh2OEm=
MIA PaCa-2 NH:xNY5HfW6ldHnvckBCe3OjeR?= Mmi5NlDDqM7:TR?= M1;Ub|I1KGh? M4jDVJJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u NG\zfG0zPTh6OES4PS=>
BxPC-3 M4jNeWZ2dmO2aX;uJGF{e2G7 MnXsNlDDqM7:TR?= NIHZT3YzPCCq M4XINJJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u MnnFNlU5QDh2OEm=
AsPC-1 MV7GeY5kfGmxbjDBd5NigQ>? M2m3N|IxyqEQvF2= NILFNG4zPCCq MVny[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= M3PmV|I2QDh6NEi5
MIA PaCa-2 NEj0d4NHfW6ldHnvckBCe3OjeR?= MXOyNOKh|ryP NUT6d4N6OjRiaB?= M2rXdYVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCge4hmdiClb33ibY5m\CC5aYToJIdtfWOxc3WgZY5idG:pcx?= MoHwNlU5QDh2OEm=
MIA PaCa-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX2NlDDqM7:TR?= MXuyJIg> MmrFd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm M4LRSFI2QDh6NEi5
BxPC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W2XVIxyqEQvF2= NX62Rlk5OiCq NVTZbmJEe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On M1XpfFI2QDh6NEi5
AsPC-1 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyNOKh|ryP MlXoNkBp MoS2d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NXf1N4lKOjV6OEi0PFk>
HEY NW\DN45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS5fFgzOMLizszN NXXoPZdSOiCq Mo\nd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MUWyOVg5QDR6OR?=
OVCAR-3 M2mzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzsZ2czOMLizszN NILzOVAzKGh? MUXz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MkTqNlU5QDh2OEm=
SK-OV-3 NFPhPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjaZlFPOjEEoN88US=> Mm[0NkBp MlLid4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NGL4ZWozPTh6OES4PS=>
MH7A  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP1NWhuOjRiaB?= NX\RTHpbemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?= NFzYXGEzPTh4Mkm2Oi=>
MH7A  MYfBdI9xfG:|aYOgRZN{[Xl? NX;WV2ZuOjVizszN NYnzUIVmOjRiaB?= NUDtRXN4emW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N MV2yOVg3Ojl4Nh?=
SCC25 MmDmSpVv[3Srb36gRZN{[Xl? NH;pPWczOCEQvF2= Mn3jNlQhcA>? MUPpcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu MVmyOVg{PDRyMB?=
HaCaT  M1Swd2Z2dmO2aX;uJGF{e2G7 NE\oTnc2KML3TR?= M1joN|I1KGh? NIHvWlNqdmirYnn0d{BKTk5vzsOtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? MnrpNlU5OzR|NUO=
HaCaT  NGTTOIpHfW6ldHnvckBCe3OjeR?= MkmxOUDDvU1? NGHNUFIzPCCq NEPKcY9qdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? NYHTSFZVOjV6M{SzOVM>
HPAEpiCs  MVnGeY5kfGmxbjDBd5NigQ>? NXiyR5hVOS9|L{GwJO69VQ>? MoHkNUBp M{DFWpJm\HWlZYOgV|FRNWmwZIXj[YQhUUODTT2xJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHl? M3;LOFI2PzN2OUCw
HPAEpiCs M1LOfGZ2dmO2aX;uJGF{e2G7 NH7lfFMyNzNxMUCg{txO NXPGPIo2OSCq M1XLWYlvcGmkaYTzJHMyWC2|dHnteYxifGWmIFHreEBxcG:|cHjvdplt[XSrb36gJOKh NYXPVWFVOjV5M{S5NFA>
HPAEpiCs MVXGeY5kfGmxbjDBd5NigQ>? NHHqPYsyNzNxMUCg{txO NX;RfJVjOSCq M{jaZ4lvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u M3HQN|I2PzN2OUCw
K562 NFHqZWFHfW6ldHnvckBCe3OjeR?= NX7qdY1mOTEEoN88US=> MlvGNeKhcA>? MlfPSG1UVw>? NYHmXI1lcW6qaXLpeJMheXWrbnHjdolv\S2rbnT1Z4VlKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> Mn3kNlU3QDRyNEO=
PANC-1 M2WzUmZ2dmO2aX;uJGF{e2G7 MnrsNVAh|ryP MmK0NUBp MmLP[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? NYjHOXJXOjV4M{KyNlI>
BxPC-3 NVLsSJRNTnWwY4Tpc44hSXO|YYm= NHfJVoIyOCEQvF2= NWfI[FdKOSCq MVPlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>? NInZZm8zPTZ|MkKyNi=>
K562  NEDkTolHfW6ldHnvckBCe3OjeR?= MoPlNE4zPS1zIN88US=> MW[yOEBp MYnzeZBxemW|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25? M1nRWVI2PjF7M{my
THP-1 Moq1SpVv[3Srb36gRZN{[Xl? MmDTOUDDvU1? NWK0eFdEOiCq M{nheZNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi MWKyOVU6QDZ4MR?=
WB NWDBTJlFTnWwY4Tpc44hSXO|YYm= MYCyNQKBkc7:TdMg NHP0R5Y{OOLCiX3pci=> NXzSUXNq\GWlcnXhd4V{KHSqZTDMVHMuKG:{IFzURU1qdmS3Y3XkJGlNNTZiYX7kJHRPTi4QsdMgdJJw\HWldHnvci=> MY[yOVU{ODZ6Mh?=
RAW 264.7 M3P6TWZ2dmO2aX;uJGF{e2G7 Mor5NVDDqM7:TR?= M3rWNFMx6oDLbXnu MlTzbY5lfWOnczDjbIFz[WO2ZYLpd5Rq[yC4YXP1c4xifGmxbjDv[kBQS3QEoB?= NELG[4czPTR4MUO5PS=>
RAW 264.7 NYrwcplHTnWwY4Tpc44hSXO|YYm= M2myVlExyqEQvF2= NHroSpM{OOLCiX3pci=> MnPoZZR1\W63YYTld{B1cGViZX\m[YN1eyCxZjDPVGchd25ib4P0[Y9kdGG|dDDy[ZRz[WO2aX;u NHfqdVYzPTR4MUO5PS=>
HaCaT  NWnIWGxJTnWwY4Tpc44hSXO|YYm= MlnZOFDDqM7:TR?= NXXiOYgyOy1{NDDo Mn3CSG1UVw>? MV3y[YR2[2W|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>? M3rHNVI2PDN3NEi1
H9c2 NFnvcmtHfW6ldHnvckBCe3OjeR?= NH3vZ2w2OMLizszNxsA> MVuxNkBp NWTV[3ZHemWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O= NFq0cFQzPTJ2NUixPC=>
HSCs NH3WWWVCeG:ydH;zbZMhSXO|YYm= MWiyOUDPxE1? MX[yOOKhcA>? NIXYU2x{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:|aYO= M{nEblI1QTZzOUWw
THP-1 NXfKbWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;sXWQ4PzJiaB?= Mn7iSG1UVw>? Ml\iTWM2OD12LkhOwG0> NXKzclRmOjR6MUWwPFc>
MDDCs NV[wWGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV23NkBp NVWzWoFZTE2VTx?= NVPoRohGUUN3MEKuO:69VQ>? M4LyUlI1QDF3MEi3
MDDCs NEHYSFdHfW6ldHnvckBCe3OjeR?= NXnBb4FrOC1zNTFOwG0> NYDNRVNkPDhiaB?= NX7ZepBXTE2VTx?= MnTmd5VxeHKnc4Pld{BKTk5vzsGgZY5lKEmSLUGwJJBzd2S3Y4Tpc47DqA>? NYXDOpJmOjR6MUWwPFc>
MDDCs NIW1XpNHfW6ldHnvckBCe3OjeR?= MYqwMVE2KM7:TR?= MmXSOFghcA>? NV[ySHVSTE2VTx?= NH[1TmpqdmirYnn0d{BOUVBvMXGsJG1KWC1zYjDhcoQhWkGQVFXTJJBzd2S3Y4Tpc44> NXnTUlBGOjR6MUWwPFc>
MDDCs NGH4ZWNHfW6ldHnvckBCe3OjeR?= MnjXNVAh|ryP MVSzMlUhcA>? MnfuSG1UVw>? NVW4NFZt[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=> NFfFNmkzPDhzNUC4Oy=>
macrophages NEjNZYFHfW6ldHnvckBCe3OjeR?= NV;HeZExOeLCid88US=> NX\ib4ROPC534pEJbC=> MYfjc41xdGW2ZXz5JIlvcGmkaYTzJG1VNUmLST3pcoR2[2WmIHHjeIl3[XSrb36gc4YhVkZvzsrC NUXtS3lzOjR6MEi2N|M>
PDL  NX3ne5o{TnWwY4Tpc44hSXO|YYm= MliwNlDDqM7:TdMg MYGzNEBucW5? MXvEUXNQ NFzDNmt{cWewaX\pZ4FvfGy7IHnubIljcXS|IITo[UB1\W6|aXzlJIZwemOnLX3l[IlifGWmIFLNVE0zKGW6cILld5Nqd25? MnntNlQ2PjFyOEG=
AGS NIXrZVlHfW6ldHnvckBCe3OjeR?= NH3kNHA2KM7:TR?= MnyzN|AhdWmw Mnj6d5VxeHKnc4Pld:KhOS2rbnT1Z4VlKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M2PtdFI1PTR5OEe4
H520 NUXYU3R[TnWwY4Tpc44hSXO|YYm= M37wU|ExyqEEtV2= MYGxJIg> M4fCNWROW09? Mn;h[IVkemWjc3XzJJRp\SCyZX3leJJmgGWmLXnu[JVk\WRiTWPINkBuWk6DIHHu[EBxem:2ZXnuJIxmfmWucx?= MnTUNlQ2OzB2N{W=
H1703 M3nsfmZ2dmO2aX;uJGF{e2G7 NF;IU5EyOMLiwsXN Mn2wNUBp NYjVXGN5TE2VTx?= NGG3XJll\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz NY\SeXM5OjR3M{C0O|U>
H520 MoDwSpVv[3Srb36gRZN{[Xl? NW\4RYNFOTEEoNM1US=> NXvKOFhrOTJiaB?= MWTEUXNQ MmTvbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7 M4PjflI1PTNyNEe1
H1703 NVWwWZpGTnWwY4Tpc44hSXO|YYm= NGHvdoEyOMLiwsXN NGTGN|MyOiCq NFHXeFVFVVOR M4TjdolvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?= MYCyOFU{ODR5NR?=
H520 MmT4SpVv[3Srb36gRZN{[Xl? NX7JTG9ZOTEEoNM1US=> M4G5VVYhcA>? MVHEUXNQ NU\YelYxe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l MXeyOFU{ODR5NR?=
H1703 MU\GeY5kfGmxbjDBd5NigQ>? NWrlfo0{OTEEoNM1US=> MUW2JIg> NH7Ce4tFVVOR NFPoPXV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW= MYmyOFU{ODR5NR?=
MC3T3-E1 NV76UHVpTnWwY4Tpc44hSXO|YYm= MXmwMlMwOy9|MDFOwG0> MY[xJIg> NHjNeolifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36gbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYNCpC=> MlvoNlQ2ODJ4OU[=
MC3T3-E1 M1fXOWZ2dmO2aX;uJGF{e2G7 Mn7wN|Ah|ryP NUX3RoFsOSCq MWjheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= NYSwT3BUOjR3MEK2PVY>
HUVECs  M13zOmZ2dmO2aX;uJGF{e2G7 Mm\2NVDDqML3TR?= MYKxJIg> MWrpcohq[mm2czDUUmYu|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v MnHkNlQ1QDd7NkS=
AGS  NV\HVlZ4TnWwY4Tpc44hSXO|YYm= NWTrem1rOTEEoNM1US=> MkTYN|DDqG2rbh?= MUTpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? NVPUXWVzOjR2N{m2PFE>
MKN-45 M3rKcWZ2dmO2aX;uJGF{e2G7 NH3zdlUyOMLiwsXN NUL1e|Y1OzEEoH3pci=> M33rPYlvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6 MWeyOFQ4QTZ6MR?=
AGS  NX\3[INDTnWwY4Tpc44hSXO|YYm= M2r5OFExyqEEtV2= NUPNRo5iOzEEoH3pci=> NWPHW2RD[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? NU\NWHlSOjR2N{m2PFE>
MKN-45 NFLTZWZHfW6ldHnvckBCe3OjeR?= NEn5Z|cyOMLiwsXN MnKyN|DDqG2rbh?= M{T0NIF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v M4XWU|I1PDd7Nkix
AGS  Mn\4SpVv[3Srb36gRZN{[Xl? Ml\mNVDDqML3TR?= Ml3ZN|DDqG2rbh?= M{fpSJNq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w M2jHUlI1PDd7Nkix
MKN-45 NWD1T4ZzTnWwY4Tpc44hSXO|YYm= NIXJcmcyOMLiwsXN NXnJ[m1KOzEEoH3pci=> M3;lfZNq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w M13DNFI1PDd7Nkix
DCs M{[4NWZ2dmO2aX;uJGF{e2G7 MVOyNOKh|ryP MkLVNeKhcA>? MXvk[YNz\WG|ZYOgTWwuOTJicILv[JVkfGmxbh?= Mn\CNlQ1OzR4M{[=
HUVEC  MUfGeY5kfGmxbjDBd5NigQ>? Mn7LNlAh|ryvwrC= MmrNOUBp NV;nNnVFTE2VTx?= MWjy[YR2[2W|IHP5eI9scW6nIHX4dJJme3Orb36gcIV3\Wy|IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MUiyOFE5QTB4Mh?=
A 549 NVzvR3VDTnWwY4Tpc44hSXO|YYm= MXS1NEDPxE1? NF7lTmgyKGh? NFH3XWhl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>? MkLtNlQyPzl4OEi=
H520  MVHGeY5kfGmxbjDBd5NigQ>? NHviXIQ2NzFyIN88US=> MXmxJIg> NFTtd4JFVVOR NVHBO5ln\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> NXryNXplOjRzM{i5NFM>
H1703  MoXxSpVv[3Srb36gRZN{[Xl? M2DJNVUwOTBizszN MlXMNUBp NYD0O205TE2VTx?= NHzNRXFl\WO{ZXHz[ZMhVVOKMjDwdo91\WmwIHHzJJdmdGxiYYOgcXJPSSCuZY\lcJMhcW5iZ3XmbZRqdmmkLXX4dI9{\WRiY3XscC=> MX[yOFE{QDlyMx?=
H520  NYrCZ|JLTnWwY4Tpc44hSXO|YYm= NH7DU2wyOMLiwsXN NIfaRVkyOiCq NH[xNo5FVVOR MX3k[YNz\WG|ZYOgUXNJOiCvUl7BJIFv\CCycn;0[YlvKHO2YXLpcIl1gSCrbjDn[YZqfGmwaXKteJJm[XSnZDDOV2NNSyClZXzsdy=> NFroZXczPDF|OEmwNy=>
H1703  MXTGeY5kfGmxbjDBd5NigQ>? NWSyPYRCOTEEoNM1US=> Ml\sNVIhcA>? MVnEUXNQ NXT3cmIy\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? MoXDNlQyOzh7MEO=
MCF-7  NWnqNGpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCxNOKh|ryP NHX0OFQzPMLiaB?= M3LieolvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg> MViyOFEzQDh3Mx?=
HPAEpiCs NWHvOIdJTnWwY4Tpc44hSXO|YYm= M3ryWFAvOS9zL{GwJO69VQ>? MkXKNUBp NWT3SmdtcW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ3BNSTMEoIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbh?= M2rJblI1ODZ7MUW4
podocytes M1jUSWZ2dmO2aX;uJGF{e2G7 MWexNOKh|ryP M2C2NlEhcA>? MX7pcohq[mm2czDUS2bPujFvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFugZY5lKEW{a{GvNuKh M3fXe|I1ODN4MkGy
MCF-7 MnuySpVv[3Srb36gRZN{[Xl? Ml7rNVDDqM7:TR?= NY\qR|JEOSCq MYDEUXNQ Ml3NdoVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=> NGXUTZgzPDBzOUC5NC=>
MCF-7 NUG0SWxCTnWwY4Tpc44hSXO|YYm= MYGxNOKh|ryP NHrPXnkzPCCq M2TpZ2ROW09? NEniTmJqdmO{ZXHz[ZMhfGinIGfBMYlv\HWlZXSgZZBweHSxc3nz M{jldFI1ODF7MEmw
HAPI MULGeY5kfGmxbjDBd5NigQ>? M4izPFExNzJyL{SwxsDPxE1? MWmxJIg> MWfpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>? NFn3V40zOzl4OUGyNC=>
HAPI NVOwVlZnTnWwY4Tpc44hSXO|YYm= MX[yNOKh|ryPwrC= Ml63NUBp MUHEUXNQ NH;TU3FifHSnboXheIV{KFSFRFStbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGmQT2OgZY5lKHC{b3T1Z5Rqd25? M2\lc|I{QTZ7MUKw
HepG2 NFjQdGpHfW6ldHnvckBCe3OjeR?= NX;yeW5QOzVyIH7N NIXGUGszPCCq M4\OTolvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?= MmG5NlM6OzNzOUi=
AGS  MU\GeY5kfGmxbjDBd5NigQ>? NYm4Wo0xOTEEoN88US=> NFXSS24{OCCvaX6= MXjpcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt? Mn7uNlM5PTB7OUS=
HepG2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMVUxKM7:TR?= MoTxOFghcA>? M1zrU4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M4TRR|I{QDB5NUC4
BEL7404 NFrPclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[wNlAuPTBizszN NEnUW2w1QCCq M3LjZYlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MX6yN|gxPzVyOB?=
HL7702 Mkn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjMT2oxNTVyIN88US=> NE[4fXU1QCCq MneybY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MWSyN|gxPzVyOB?=
HepG2 NIOwXHJHfW6ldHnvckBCe3OjeR?= M4fEd|AuPTBizszN NFPLU3QzPCCq M1PwWIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26|dILlZY0heHKxdHXpcpMhVUGSS1HQT|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2PCUVI{QDB5NUC4
BEAS-2B M4PwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XqSVExKM7:TR?= MVqzNEBucW5? NVjhOHkxemW4ZYLz[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgTGNK MlfrNlM4QDRyM{S=
BEAS-2B Mnn1R5l1d3SxeHn0fUBCe3OjeR?= MmLkNVAh|ryP M17FN|MxKG2rbh?= MWHpcohq[mm2ZXSgeIhmKGmwY4LlZZNmKGmwIFzETEBidmRiSVytPEBmgHC{ZYPzbY9v NWnVZWxsOjN5OESwN|Q>
BEAS-2B MoT0SpVv[3Srb36gRZN{[Xl? NHyzVHkyOCEQvF2= NHTIR3g{OCCvaX6= NYW0VHZH\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD[WRiYX7kJIZiew>? M3X3XVI{Pzh2MEO0
H9c2  Ml7sSpVv[3Srb36gRZN{[Xl? NF3iXWExNjBzL{CuNU8yKM7:TR?= MonoNUBp MWPheJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25uIH3SUmEhdGW4ZXzzMEBidmRicILvcY91\XJiYXP0bZZqfHl? NIG1dXEzOzd5NEK1Ni=>
H9c2  M4rr[mZ2dmO2aX;uJGF{e2G7 MmHGNUDPxE1? MnTlNUBp MnHLdoVlfWOnczDUUmYu|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? MV[yN|c4PDJ3Mh?=
U937 M3HxTWZ2dmO2aX;uJGF{e2G7 M3HWV|ExyqEQvF5CpC=> M1\WRlEhcA>? MYThZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6|Y4LpdJRqd26jbDDs[ZZmdHN? M2PU[lI{PzB5M{i3
U937 Ml;GSpVv[3Srb36gRZN{[Xl? MnHaNVDDqM7:TdMg M3L5fVEhcA>? NEfqfHli[nKxZ3H0[ZMh[2GoZnXpcoUucW6mdXPl[EBOU1BvMTDkc5dvNXKnZ4XsZZRqd25iYX7kJHBROkGlzsGgeZAuemWpdXzheIlwdg>? MYmyN|cxPzN6Nx?=
U937 MUfGeY5kfGmxbjDBd5NigQ>? NFfUWVcyOMLizszNxsA> NGC1WpUyKGh? NEPlNo9{fXCycnXzd4V{KGNvSoXuJIFv\CCFUlXCJJBpd3OyaH;yfYxifGmxbjDpckBk[W[oZXnu[U11emWjdHXkJINmdGy|wrC= MlHYNlM4ODd|OEe=
A549 NVHpO3BoTnWwY4Tpc44hSXO|YYm= M1\xdlAvOy9|L{OwJO69VQ>? MVyxJIg> NV;5eIlme2mpbnnmbYNidnSueTDheJRmdnWjdHXzJGFVWM7|Uz3t[YRq[XSnZDDDU3guOiCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iYX7kJJBzd22xdHXyJIFkfGm4aYT5xsA> NYfKS2x1OjN4OEC2O|Q>
A549 NUWyeIhrTnWwY4Tpc44hSXO|YYm= MnW4NVDDqM7:TdMg NGL4XGkxNTNyIH3pci=> NXr0OG95cW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? M{DpUFI{PjhyNke0
A549 NUjofVBkTnWwY4Tpc44hSXO|YYm= NHjEbIwyOMLizszNxsA> MUKxJIg> NGHOcZZqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= NUSzUFV6OjN4OEC2O|Q>
A549 MoLsSpVv[3Srb36gRZN{[Xl? MX6xNOKh|ryPwrC= NHjZVW8yKGh? MnS0doVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>? NEf4XmUzOzZ6ME[3OC=>
A549 M2DwNWZ2dmO2aX;uJGF{e2G7 MmDTNVDDqM7:TdMg M2HuR|EhcA>? NV7uUGRjemWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA> NFXUSXEzOzZ6ME[3OC=>
PC12 NUH5TJpjTnWwY4Tpc44hSXO|YYm= MljsNVAwOjBxNECg{txO NVWwSZBuOcLiaB?= MmDYbY5pcWKrdIOgTm5MKGGwZDDwN|g> NXjaNIJLOjN3OESzOVc>
HK-2 M4nybGFxd3C2b4Ppd{BCe3OjeR?= NU\rNXF4OjEEoN88US=> NILBUpAzPCCq MXTpcohq[mm2czDFVmsh[W6mIICzPG1CWEt? NIfONpYzOzV2M{G1NS=>
H9c2 M1HIUmZ2dmO2aX;uJGF{e2G7 MoC5NeKh|ryP MkHMNUBp MX\y[YR2[2W|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= Mo\pNlM{PTN4OUm=
H9c2 NXzONnpxTnWwY4Tpc44hSXO|YYm= MlnMNeKh|ryP MVuxJIg> MWPy[YR2[2W|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5 M2H6OVI{OzV|Nkm5
H1650  NYrCXpBxTnWwY4Tpc44hSXO|YYm= MXuxNOKh|ryPwrC= M4jSV|EhcA>? NUfWO5N4TE2VTx?= MkX1[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>? MmPkNlMzOjh4OU[=
H1703 M1LvOWZ2dmO2aX;uJGF{e2G7 M2fWTFExyqEQvF5CpC=> MkHINUBp NWHvOVV2TE2VTx?= M2iyRYRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? NIXieFUzOzJ{OE[5Oi=>
H1650  NWDvTYVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLJNVDDqM7:TdMg NFLZOnQyKGh? NWDp[2VZTE2VTx?= M1:5UYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NXfNd21VOjN{Mki2PVY>
H1703 NVjFWm0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNOKh|ryPwrC= Ml\2NUBp MVHEUXNQ MYrlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NHTGU|QzOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID